Lys160
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Sumoylation Site Page: > Lys160  -  PML (human)

Site Information
EAHQWFLkHEARPLA   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 2295400

In vivo Characterization
Methods used to characterize site in vivo:
electrophoretic mobility shift ( 17 , 18 ) , immunoassay ( 18 , 19 ) , mass spectrometry ( 5 , 6 ) , mutation of modification site ( 2 , 3 , 7 , 9 , 11 , 14 , 15 , 16 , 17 , 18 , 19 , 20 ) , western blotting ( 2 , 14 , 17 , 18 )
Disease tissue studied:
bone cancer ( 11 , 15 , 16 ) , glioblastoma multiforme ( 18 ) , glioma ( 18 ) , lung cancer ( 16 ) , non-small cell lung cancer ( 16 ) , oropharyngeal cancer ( 17 ) , squamous cell carcinoma of the oropharynx ( 17 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Treatments:
As2O3 ( 18 )

Downstream Regulation
Effects of modification on PML:
intracellular localization ( 9 , 15 , 18 , 19 , 20 ) , molecular association, regulation ( 3 , 16 , 18 ) , protein degradation ( 17 , 18 )
Effects of modification on biological processes:
carcinogenesis, induced ( 15 ) , cell differentiation, inhibited ( 15 ) , cell growth, altered ( 15 ) , transcription, induced ( 7 , 11 ) , transcription, inhibited ( 15 )
Induce interaction with:
PIAS1 (human) ( 3 ) , PSME1 (human) ( 18 )
Inhibit interaction with:
MDM2 (human) ( 16 )

Disease / Diagnostics Relevance
Relevant diseases:
leukemia ( 15 )

References 

1

Lumpkin RJ, et al. (2017) Site-specific identification and quantitation of endogenous SUMO modifications under native conditions. Nat Commun 8, 1171
29079793   Curated Info

2

Schilling EM, et al. (2017) The Human Cytomegalovirus IE1 Protein Antagonizes PML Nuclear Body-Mediated Intrinsic Immunity via the Inhibition of PML De Novo SUMOylation. J Virol 91
27903803   Curated Info

3

Brown JR, et al. (2016) SUMO Ligase Protein Inhibitor of Activated STAT1 (PIAS1) Is a Constituent Promyelocytic Leukemia Nuclear Body Protein That Contributes to the Intrinsic Antiviral Immune Response to Herpes Simplex Virus 1. J Virol 90, 5939-52
27099310   Curated Info

4

Ferhi O, et al. (2016) Comment on "SUMO deconjugation is required for arsenic-triggered ubiquitylation of PML". Sci Signal 9, tc1
27507651   Curated Info

5

Hendriks IA, et al. (2014) Uncovering global SUMOylation signaling networks in a site-specific manner. Nat Struct Mol Biol 21, 927-36
25218447   Curated Info

6

Tammsalu T, et al. (2014) Proteome-wide identification of SUMO2 modification sites. Sci Signal 7, rs2
24782567   Curated Info

7

Liu ST, et al. (2013) Dual roles for lysine 490 of promyelocytic leukemia protein in the transactivation of glucocorticoid receptor-interacting protein 1. Biochim Biophys Acta 1833, 1799-810
23542129   Curated Info

8

Rabellino A, et al. (2012) The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA. Cancer Res 72, 2275-84
22406621   Curated Info

9

Brand P, Lenser T, Hemmerich P (2010) Assembly dynamics of PML nuclear bodies in living cells. PMC Biophys 3, 3
20205709   Curated Info

10

Percherancier Y, et al. (2009) Role of SUMO in RNF4-mediated promyelocytic leukemia protein (PML) degradation: sumoylation of PML and phospho-switch control of its SUMO binding domain dissected in living cells. J Biol Chem 284, 16595-608
19380586   Curated Info

11

Santiago A, et al. (2009) Identification of two independent SUMO-interacting motifs in Daxx: evolutionary conservation from Drosophila to humans and their biochemical functions. Cell Cycle 8, 76-87
19106612   Curated Info

12

Lallemand-Breitenbach V, et al. (2008) Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 10, 547-55
18408733   Curated Info

13

Tagata Y, et al. (2008) Phosphorylation of PML is essential for activation of C/EBP epsilon and PU.1 to accelerate granulocytic differentiation. Leukemia 22, 273-80
17989716   Curated Info

14

Gong L, Yeh ET (2006) Characterization of a family of nucleolar SUMO-specific proteases with preference for SUMO-2 or SUMO-3. J Biol Chem 281, 15869-77
16608850   Curated Info

15

Zhu J, et al. (2005) A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell 7, 143-53
15710327   Curated Info

16

Wei X, et al. (2003) Physical and functional interactions between PML and MDM2. J Biol Chem 278, 29288-97
12759344   Curated Info

17

Boutell C, Orr A, Everett RD (2003) PML residue lysine 160 is required for the degradation of PML induced by herpes simplex virus type 1 regulatory protein ICP0. J Virol 77, 8686-94
12885887   Curated Info

18

Lallemand-Breitenbach V, et al. (2001) Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med 193, 1361-71
11413191   Curated Info

19

Zhong S, et al. (2000) Role of SUMO-1-modified PML in nuclear body formation. Blood 95, 2748-52
10779416   Curated Info

20

Kamitani T, et al. (1998) Identification of three major sentrinization sites in PML. J Biol Chem 273, 26675-82
9756909   Curated Info